reports
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sust...
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgrou...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company’s common stock with an exercise price of $12.49, the closing trading price of the Company’s common stock on the Nasd...
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtu...
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET. A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the C...
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Pr...
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of Descartes-08 in systemic lupus erythematosus ongoing with expected data readout in 2H25 Company expects to initiate Phase 2 pediatric basket trial of Decartes-08 in select autoimmune indications in 2H25 Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $214.3...
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company’s common stock with an exercise price of $17.50, the closing trading price of the Company’s common stock on the Nasdaq Global Mar...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March: A fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference at 1:00 p.m. ET on Tuesday, February 25, 2025A presentation at the TD Cowen 45th Annual Health Care Conference...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Discover Financial Services and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 February 2025 in which we reassessed the appropriateness of the ratings in th...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On February 3, 2025, the Company issued to these employees options to purchase an aggregate of 168,360 shares of the Company’s common stock with an exercise price of $19.89, the closing trading price of the Company’s common stock on ...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agree...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis Trial on track to commence in 1H25 FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA...
Discover Financial Services Reports Fourth Quarter 2024 Net Income of ...
RIVERWOODS, Ill.--(BUSINESS WIRE)-- Discover Financial Services (NYSE: DFS) Fourth Quarter 2024 Results 2024 2023 YOY Change Total loans, end of period (in billions) $121.1 $128.4 (6%) Total revenue net of interest expense (in millions) $4,759 $4,180 14% Total net charge-off rate 4.64% 4.11% 53 bps Net income (in millions) $1,291 $366 253% Diluted EPS $5.11 $1.45 252% Discover Financial Services (NYSE: DFS) today reported net i...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Prioriti...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia gravis; Safety profile continues to support outpatient administration based on updated data shared in December 2024 Phase 2 systemic lupus erythematosus (SLE) trial of Descartes-08 ongoing with expected data readout in 2H25 Cash resources expected to support pla...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324 shares of the Company’s common stock with an exercise price of $16.93, the closing trading price of the Company’s common stock on t...
Discover Financial Services Announces Fourth Quarter 2024 Earnings Rel...
RIVERWOODS, Ill.--(BUSINESS WIRE)-- Discover Financial Services (NYSE: DFS) plans to report its Fourth quarter 2024 results after the market closes on Wednesday, January 22, 2025. The earnings release will be available through Discover's Investor Relations website at . A conference call to discuss the firm's results and related matters will be held on Thursday, January 23, 2025, at 7:00 a.m. Central Time and will be limited to prepared remarks. The live audio webcast will be accessible to the general public through Discover’s Investor Relations website at . An audio replay will be available ...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company’s common stock with an exercise price of $20.12, the closing trading price of the Company’s common stock on ...
- Jonathan Moreland
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
CULP CULP INC.
NSC NORFOLK SOUTHERN CORPORATION
PMD PSYCHEMEDICS CORP.
DMLP DORCHESTER MINERALS L.P.
BBDC BARINGS BDC INC.
DBI DESIGNER BRANDS INC. CLASS A
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
RZLT REZOLUTE
CTGO INC.
NOTV CONTANGO ORE INC.
TRIN INOTIV
IBRX INC.
GRNT TRINITY CAPITAL INC
AVDL IMMUNITYBIO INC
MIO GRANITE RIDGE RESOURCES INC
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
Discover Survey: Save More, Earn More and Spend Less Are Top 2025 Fina...
RIVERWOODS, Ill.--(BUSINESS WIRE)-- Just over half (54%) of U.S. consumers plan to make a financial resolution for 2025, according to a new national survey conducted by Discover® Personal Loans. The top financial resolutions in America are to save more in general (42%), earn more (35%), spend less (35%), improve credit scores (27%), build an emergency fund (26%) and pay off or consolidate debt (21%). This press release features multimedia. View the full release here: According to a new national survey from Discover® Personal Loans, 54% of American consumers plan to make a financial resolution...
Discover® Recognized as a Best Place to Work for IT Professionals for ...
RIVERWOODS, Ill.--(BUSINESS WIRE)-- Foundry's has named Discover a 2025 Best Place to Work in IT. This annual award recognizes the top organizations that challenge their technology employees while providing great benefits and upskilling opportunities. Now in its twenty-first year being recognized, Discover ranks no. 27 among large organizations with over 5,000 employees on the Best Places to Work in IT list. The list is compiled based on a comprehensive questionnaire regarding company offerings in categories such as benefits, career development, DEI, future of work, training and retention. ...
Cartesian Therapeutics Announces Positive Updated Results from Phase 2...
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo Deepening responses observed over time in Phase 2b trial, with Descartes-08-treated participants observed to have a 5.5-point reduction in MG-ADL at Month 4 Durable responses observe...
Discover Financial Services Receives NYSE Notice Regarding Filing of F...
RIVERWOODS, Ill.--(BUSINESS WIRE)-- Discover Financial Services (NYSE: DFS) (the “Company”) today announced, as required under the New York Stock Exchange (the “NYSE”) Listed Company Manual, that it received a notice (the “NYSE Notice”) from the NYSE on November 19, 2024 that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission (the “SEC”) prior to November 18, 2024, the end of the extensi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.